Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - JOUR LB - 1. AU - Ebers, GC AU - Bulman, DE AU - Sadovnick, AD AU - Paty, DW AU - Warren, S AU - Hader, W TI - A population-based study of multiple sclerosis in twins J2 - N Engl J Med PY - 1986 VL - 315 SP - 1638 EP - 1642 UR - https://doi.org/10.1056/NEJM198612253152603 ER - TY - JOUR LB - 2. AU - Mumford, CJ AU - Wood, NW AU - Kellar-Wood, H AU - Thorpe, JW AU - Miller, DH AU - Compston, DA TI - The British Isles survey of multiple sclerosis in twins J2 - Neurology PY - 1994 VL - 44 SP - 11 EP - 15 UR - https://doi.org/10.1212/WNL.44.1.11 ER - TY - JOUR LB - 3. AU - Sadovnick, AD AU - Armstrong, H AU - Rice, GP AU - Bulman, D AU - Hashimoto, L AU - Paty, DW TI - A population-based study of multiple sclerosis in twins: update J2 - Ann Neurol PY - 1993 VL - 33 SP - 281 EP - 285 UR - https://doi.org/10.1002/ana.410330309 ER - TY - JOUR LB - 4. AU - Granieri, E AU - Casetta, I AU - Tola, MR AU - Ferrante, P TI - Multiple sclerosis: infectious hypothesis J2 - Neurol Sci PY - 2001 VL - 22 SP - 179 EP - 185 UR - https://doi.org/10.1007/s100720170021 ER - TY - JOUR LB - 5. AU - Lassmann, H AU - Niedobitek, G AU - Aloisi, F AU - Middeldorp, JM AU - NeuroproMiSe EBV Working Group TI - Epstein–Barr virus in the multiple sclerosis brain: a controversial issue – report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria J2 - Brain PY - 2011 VL - 134 SP - 2772 EP - 2786 UR - https://doi.org/10.1093/brain/awr197 ER - TY - JOUR LB - 6. AU - Owens, GP AU - Bennett, JL TI - Trigger, pathogen, or bystander: the complex nexus linking Epstein–Barr virus and multiple sclerosis J2 - Mult Scler PY - 2012 VL - 18 SP - 1204 EP - 1208 UR - https://doi.org/10.1177/1352458512448109 ER - TY - JOUR LB - 7. AU - Pohl, D TI - Epstein–Barr virus and multiple sclerosis J2 - J Neurol Sci PY - 2009 VL - 286 SP - 62 EP - 64 UR - https://doi.org/10.1016/j.jns.2009.03.028 ER - TY - JOUR LB - 8. AU - Radić, M AU - Martinović Kaliterna, D AU - Radić, J TI - Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis J2 - Neth J Med PY - 2010 VL - 68 SP - 348 EP - 353 ER - TY - JOUR LB - 9. AU - Mackenzie, IS AU - Morant, SV AU - Bloomfield, GA AU - MacDonald, TM AU - O’Riordan, J TI - Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database J2 - J Neurol Neurosurg Psychiatry PY - 2014 VL - 85 SP - 76 EP - 84 UR - https://doi.org/10.1136/jnnp-2013-305450 ER - TY - JOUR LB - 10. AU - Confavreux, C AU - Vukusic, S TI - The natural history of multiple sclerosis J2 - Rev Prat PY - 2006 VL - 56 SP - 1313 EP - 1320 UR - https://doi.org/10.1016/b978-0-443-07271-0.50006-9 ER - TY - ELEC LB - 11. AU - National Multiple Sclerosis Society TI - Clinically Isolated Syndrome (CIS) UR - www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/diagnosing-ms/cis/index.aspx M1 - 23 October 2015 ER - TY - ELEC LB - 12. AU - MS-UK TI - Choices: Types of MS PY - 2014 UR - www.ms-uk.org/files/choices_types.pdf M1 - 4 November 2015 ER - TY - ELEC LB - 13. AU - Multiple Sclerosis Trust TI - Types of MS: Rapidly Evolving Severe Relapsing Remitting MS PY - 2014 UR - www.mstrust.org.uk/a-z/types-ms M1 - 4 November 2015 ER - TY - JOUR LB - 14. AU - Miller, DH AU - Leary, SM TI - Primary-progressive multiple sclerosis J2 - Lancet Neurol PY - 2007 VL - 6 SP - 903 EP - 912 UR - https://doi.org/10.1016/S1474-4422(07)70243-0 ER - TY - JOUR LB - 15. AU - Lublin, FD AU - Reingold, SC TI - Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis J2 - Neurology PY - 1996 VL - 46 SP - 907 EP - 911 UR - https://doi.org/10.1212/WNL.46.4.907 ER - TY - JOUR LB - 16. AU - Kurtzke, JF TI - Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) J2 - Neurology PY - 1983 VL - 33 SP - 1444 EP - 1452 UR - https://doi.org/10.1212/WNL.33.11.1444 ER - TY - JOUR LB - 17. AU - Wingerchuk, DM AU - Carter, JL TI - Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies J2 - Mayo Clin Proc PY - 2014 VL - 89 SP - 225 EP - 240 UR - http://dx.doi.org/10.1016/j.mayocp.2013.11.002 ER - TY - JOUR LB - 18. AU - Runkel, L AU - Meier, W AU - Pepinsky, RB AU - Karpusas, M AU - Whitty, A AU - Kimball, K TI - Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta) J2 - Pharm Res PY - 1998 VL - 15 SP - 641 EP - 649 UR - https://doi.org/10.1023/A:1011974512425 ER - TY - JOUR LB - 19. AU - Zhang, J AU - Hutton, G AU - Zang, Y TI - A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis J2 - Clin Ther PY - 2002 VL - 24 SP - 1998 EP - 2021 UR - https://doi.org/10.1016/S0149-2918(02)80094-7 ER - TY - JOUR LB - 20. AU - Plosker, GL TI - Interferon-β-1b: a review of its use in multiple sclerosis J2 - CNS Drugs PY - 2011 VL - 25 SP - 67 EP - 88 UR - http://dx.doi.org/10.2165/11206430-000000000-00000 ER - TY - BOOK LB - 21. AU - Joint Formulary Committee TI - British National Formulary ET - 70 ed. CY - London PB - BMJ Group and Pharmaceutical Press PY - 2015 ER - TY - ELEC LB - 22. AU - Teva Pharmaceuticals Ltd TI - Copaxone 20 mg/ml, Solution for Injection, Pre-Filled Syringe. Summary of Product Characteristics UR - www.medicines.org.uk/emc/medicine/17516#PHARMACODYNAMIC_PROPS M1 - 21 April 2017 ER - TY - JOUR LB - 23. AU - La Mantia, L AU - Munari, LM AU - Lovati, R TI - Glatiramer acetate for multiple sclerosis J2 - Cochrane Database Syst Rev PY - 2010 VL - 5 SP - CD004678 UR - http://dx.doi.org/10.1002/14651858.CD004678.pub2 ER - TY - ELEC LB - 24. AU - National Institute for Health and Care Excellence TI - Beta Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis PY - 2002 UR - www.nice.org.uk/Guidance/TA32 M1 - 15 May 2016 ER - TY - JOUR LB - 25. AU - Trapp, BD AU - Nave, K-A TI - Multiple sclerosis: an immune or neurodegenerative disorder? J2 - Annu Rev Neurosci PY - 2008 VL - 31 SP - 247 EP - 269 UR - https://doi.org/10.1146/annurev.neuro.30.051606.094313 ER - TY - JOUR LB - 26. AU - Trapp, BD AU - Peterson, J AU - Ransohoff, RM AU - Rudick, R AU - Mörk, S AU - Bö, L TI - Axonal transection in the lesions of multiple sclerosis J2 - N Engl J Med PY - 1998 VL - 338 SP - 278 EP - 285 UR - http://dx.doi.org/10.1056/NEJM199801293380502 ER - TY - CHAP LB - 27. AU - Minagar, A TI - Multiple sclerosis: an overview of clinical features, pathophysiology, neuroimaging, and treatment options A2 - Granger, DN A2 - Granger, JP T2 - Colloquium Series on Integrated Systems Physiology: From Molecule to Function CY - San Rafael, CA PB - Morgan & Claypool Life Sciences PY - 2014 SP - 1 EP - 117 UR - https://doi.org/10.4199/c00116ed1v01y201408isp055 ER - TY - JOUR LB - 28. AU - Bjartmar, C AU - Kinkel, RP AU - Kidd, G AU - Rudick, RA AU - Trapp, BD TI - Axonal loss in normal-appearing white matter in a patient with acute MS J2 - Neurology PY - 2001 VL - 57 SP - 1248 EP - 1252 UR - https://doi.org/10.1212/WNL.57.7.1248 ER - TY - JOUR LB - 29. AU - Gourraud, PA AU - Harbo, HF AU - Hauser, SL AU - Baranzini, SE TI - The genetics of multiple sclerosis: an up-to-date review J2 - Immunol Rev PY - 2012 VL - 248 SP - 87 EP - 103 UR - http://dx.doi.org/10.1111/j.1600-065X.2012.01134.x ER - TY - JOUR LB - 30. AU - Jersild, C AU - Fog, T AU - Hansen, GS AU - Thomsen, M AU - Svejgaard, A AU - Dupont, B TI - Histocompatibility determinants in multiple sclerosis, with special reference to clinical course J2 - Lancet PY - 1973 VL - 2 SP - 1221 EP - 1225 UR - https://doi.org/10.1016/S0140-6736(73)90970-7 ER - TY - JOUR LB - 31. AU - Naito, S AU - Namerow, N AU - Mickey, MR AU - Terasaki, PI TI - Multiple sclerosis: association with HL-A3 J2 - Tissue Antigens PY - 1972 VL - 2 SP - 1 EP - 4 UR - https://doi.org/10.1111/j.1399-0039.1972.tb00111.x ER - TY - JOUR LB - 32. AU - Sawcer, S AU - Hellenthal, G AU - Pirinen, M AU - Spencer, CC AU - International Multiple Sclerosis Genetics Consortium AU - Wellcome Trust Case Control Consortium TI - Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis J2 - Nature PY - 2011 VL - 476 SP - 214 EP - 219 UR - https://doi.org/10.1038/nature10251 ER - TY - JOUR LB - 33. AU - Lincoln, MR AU - Montpetit, A AU - Cader, MZ AU - Saarela, J AU - Dyment, DA AU - Tiislar, M TI - A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis J2 - Nat Genet PY - 2005 VL - 37 SP - 1108 EP - 1112 UR - https://doi.org/10.1038/ng1647 ER - TY - JOUR LB - 34. AU - Oksenberg, JR AU - Barcellos, LF AU - Cree, BA AU - Baranzini, SE AU - Bugawan, TL AU - Khan, O TI - Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans J2 - Am J Hum Genet PY - 2004 VL - 74 SP - 160 EP - 167 UR - https://doi.org/10.1086/380997 ER - TY - JOUR LB - 35. AU - Schmidt, H AU - Williamson, D AU - Ashley-Koch, A TI - HLA-DR15 haplotype and multiple sclerosis: a HuGE review J2 - Am J Epidemiol PY - 2007 VL - 165 SP - 1097 EP - 1109 UR - https://doi.org/10.1093/aje/kwk118 ER - TY - JOUR LB - 36. AU - Muñoz-Culla, M AU - Irizar, H AU - Otaegui, D TI - The genetics of multiple sclerosis: review of current and emerging candidates J2 - Appl Clin Genet PY - 2013 VL - 6 SP - 63 EP - 73 UR - http://dx.doi.org/10.2147/TACG.S29107 ER - TY - JOUR LB - 37. AU - Willer, CJ AU - Dyment, DA AU - Risch, NJ AU - Sadovnick, AD AU - Ebers, GC AU - Canadian Collaborative Study Group TI - Twin concordance and sibling recurrence rates in multiple sclerosis J2 - Proc Natl Acad Sci USA PY - 2003 VL - 100 SP - 12877 EP - 12882 UR - http://dx.doi.org/10.1073/pnas.1932604100 ER - TY - JOUR LB - 38. AU - Baranzini, SE AU - Mudge, J AU - van Velkinburgh, JC AU - Khankhanian, P AU - Khrebtukova, I AU - Miller, NA TI - Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis J2 - Nature PY - 2010 VL - 464 SP - 1351 EP - 1356 UR - http://dx.doi.org/10.1038/nature08990 ER - TY - JOUR LB - 39. AU - Belbasis, L AU - Bellou, V AU - Evangelou, E AU - Ioannidis, JP AU - Tzoulaki, I TI - Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses J2 - Lancet Neurol PY - 2015 VL - 14 SP - 263 EP - 273 UR - http://dx.doi.org/10.1016/S1474-4422(14)70267-4 ER - TY - JOUR LB - 40. AU - Warner, HB AU - Carp, RI TI - Multiple sclerosis and Epstein–Barr virus J2 - Lancet PY - 1981 VL - 2 SP - 1290 UR - https://doi.org/10.1016/S0140-6736(81)91527-0 ER - TY - JOUR LB - 41. AU - Goodin, DS TI - The causal cascade to multiple sclerosis: a model for MS pathogenesis J2 - PLOS ONE PY - 2009 VL - 4 SP - e4565 UR - http://dx.doi.org/10.1371/journal.pone.0004565 ER - TY - JOUR LB - 42. AU - Ascherio, A AU - Munger, KL AU - Lennette, ET AU - Spiegelman, D AU - Hernán, MA AU - Olek, MJ TI - Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study J2 - JAMA PY - 2001 VL - 286 SP - 3083 EP - 3088 UR - https://doi.org/10.1001/jama.286.24.3083 ER - TY - JOUR LB - 43. AU - Pakpoor, J AU - Disanto, G AU - Gerber, JE AU - Dobson, R AU - Meier, UC AU - Giovannoni, G AU - Ramagopalan, SV TI - The risk of developing multiple sclerosis in individuals seronegative for Epstein–Barr virus: a meta-analysis J2 - Mult Scler PY - 2013 VL - 19 SP - 162 EP - 166 UR - http://dx.doi.org/10.1177/1352458512449682 ER - TY - JOUR LB - 44. AU - Serafini, B AU - Rosicarelli, B AU - Franciotta, D AU - Magliozzi, R AU - Reynolds, R AU - Cinque, P TI - Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain J2 - J Exp Med PY - 2007 VL - 204 SP - 2899 EP - 2912 UR - https://doi.org/10.1084/jem.20071030 ER - TY - JOUR LB - 45. AU - Carlyle, IP TI - Multiple sclerosis: a geographical hypothesis J2 - Med Hypotheses PY - 1997 VL - 49 SP - 477 EP - 486 UR - https://doi.org/10.1016/S0306-9877(97)90065-7 ER - TY - JOUR LB - 46. AU - Esparza, ML AU - Sasaki, S AU - Kesteloot, H TI - Nutrition, latitude, and multiple sclerosis mortality: an ecologic study J2 - Am J Epidemiol PY - 1995 VL - 142 SP - 733 EP - 737 ER - TY - JOUR LB - 47. AU - Islam, T AU - Gauderman, WJ AU - Cozen, W AU - Mack, TM TI - Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins J2 - Neurology PY - 2007 VL - 69 SP - 381 EP - 388 UR - https://doi.org/10.1212/01.wnl.0000268266.50850.48 ER - TY - JOUR LB - 48. AU - Resch, J TI - Geographic distribution of multiple sclerosis and comparison with geophysical values J2 - Soz Praventivmed PY - 1995 VL - 40 SP - 161 EP - 171 UR - https://doi.org/10.1007/BF01318637 ER - TY - JOUR LB - 49. AU - Rosen, LN AU - Livingstone, IR AU - Rosenthal, NE TI - Multiple sclerosis and latitude: a new perspective on an old association J2 - Med Hypotheses PY - 1991 VL - 36 SP - 376 EP - 378 UR - https://doi.org/10.1016/0306-9877(91)90014-P ER - TY - JOUR LB - 50. AU - Simpson, S AU - Blizzard, L AU - Otahal, P AU - Van der Mei, I AU - Taylor, B TI - Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis J2 - J Neurol Neurosurg Psychiatr PY - 2011 VL - 82 SP - 1132 EP - 1141 UR - http://dx.doi.org/10.1136/jnnp.2011.240432 ER - TY - JOUR LB - 51. AU - Koch-Henriksen, N AU - Sørensen, PS TI - The changing demographic pattern of multiple sclerosis epidemiology J2 - Lancet Neurol PY - 2010 VL - 9 SP - 520 EP - 532 UR - http://dx.doi.org/10.1016/S1474-4422(10)70064-8 ER - TY - JOUR LB - 52. AU - Duan, S AU - Lv, Z AU - Fan, X AU - Wang, L AU - Han, F AU - Wang, H AU - Bi, S TI - Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis J2 - Neurosci Lett PY - 2014 VL - 570 SP - 108 EP - 113 UR - http://dx.doi.org/10.1016/j.neulet.2014.04.021 ER - TY - JOUR LB - 53. AU - Wattjes, MP AU - Barkhof, F TI - High field MRI in the diagnosis of multiple sclerosis: high field-high yield? J2 - Neuroradiology PY - 2009 VL - 51 SP - 279 EP - 292 UR - http://dx.doi.org/10.1007/s00234-009-0512-0 ER - TY - JOUR LB - 54. AU - McDonald, WI AU - Compston, A AU - Edan, G AU - Goodkin, D AU - Hartung, HP AU - Lublin, FD TI - Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis J2 - Ann Neurol PY - 2001 VL - 50 SP - 121 EP - 127 UR - https://doi.org/10.1002/ana.1032 ER - TY - JOUR LB - 55. AU - Ge, Y TI - Multiple sclerosis: the role of MR imaging J2 - AJNR Am J Neuroradiol PY - 2006 VL - 27 SP - 1165 EP - 1176 ER - TY - JOUR LB - 56. AU - Okuda, DT AU - Mowry, EM AU - Beheshtian, A AU - Waubant, E AU - Baranzini, SE AU - Goodin, DS TI - Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome J2 - Neurology PY - 2009 VL - 72 SP - 800 EP - 805 UR - https://doi.org/10.1212/01.wnl.0000335764.14513.1a ER - TY - JOUR LB - 57. AU - Nusbaum, AO AU - Lu, D AU - Tang, CY AU - Atlas, SW TI - Quantitative diffusion measurements in focal multiple sclerosis lesions: correlations with appearance on TI-weighted MR images J2 - AJR Am J Roentgenol PY - 2000 VL - 175 SP - 821 EP - 825 UR - https://doi.org/10.2214/ajr.175.3.1750821 ER - TY - JOUR LB - 58. AU - Honce, JM TI - Gray matter pathology in MS: neuroimaging and clinical correlations J2 - Mult Scler Int PY - 2013 VL - 2013 SP - 627870 UR - http://dx.doi.org/10.1155/2013/627870 ER - TY - JOUR LB - 59. AU - Lisanti, CJ AU - Asbach, P AU - Bradley, WG TI - The ependymal ‘dot–dash’ sign: an MR imaging finding of early multiple sclerosis J2 - AJNR Am J Neuroradiol PY - 2005 VL - 26 SP - 2033 EP - 2036 ER - TY - JOUR LB - 60. AU - Janardhan, V AU - Suri, S AU - Bakshi, R TI - Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening J2 - Radiology PY - 2007 VL - 244 SP - 823 EP - 831 UR - https://doi.org/10.1148/radiol.2443051171 ER - TY - JOUR LB - 61. AU - Poser, CM AU - Brinar, VV TI - Diagnostic criteria for multiple sclerosis: an historical review J2 - Clin Neurol Neurosurg PY - 2004 VL - 106 SP - 147 EP - 158 UR - http://dx.doi.org/10.1016/j.clineuro.2004.02.004 ER - TY - JOUR LB - 62. AU - Polman, CH AU - Reingold, SC AU - Banwell, B AU - Clanet, M AU - Cohen, JA AU - Filippi, M TI - Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria J2 - Ann Neurol PY - 2011 VL - 69 SP - 292 EP - 302 UR - http://dx.doi.org/10.1002/ana.22366 ER - TY - ELEC LB - 63. AU - MS International Federation TI - Atlas of MS 2013: Mapping Multiple Sclerosis Around the World PY - 2013 UR - www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf M1 - 7 June 2016 ER - TY - JOUR LB - 64. AU - Poser, CM AU - Paty, DW AU - Scheinberg, L AU - McDonald, WI AU - Davis, FA AU - Ebers, GC TI - New diagnostic criteria for multiple sclerosis: guidelines for research protocols J2 - Ann Neurol PY - 1983 VL - 13 SP - 227 EP - 231 UR - http://dx.doi.org/10.1002/ana.410130302 ER - TY - JOUR LB - 65. AU - Tintoré, M AU - Rovira, A AU - Martinez, MJ AU - Rio, J AU - Diaz-Villoslada, P AU - Brieva, L TI - Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis J2 - AJNR Am J Neuroradiol PY - 2000 VL - 21 SP - 702 EP - 706 ER - TY - JOUR LB - 66. AU - Polman, CH AU - Reingold, SC AU - Edan, G AU - Filippi, M AU - Hartung, HP AU - Kappos, L TI - Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria’ J2 - Ann Neurol PY - 2005 VL - 58 SP - 840 EP - 846 UR - http://dx.doi.org/10.1002/ana.20703 ER - TY - JOUR LB - 67. AU - Kurtzke, JF TI - On the origin of EDSS J2 - Mult Scler Relat Disord PY - 2015 VL - 4 SP - 95 EP - 103 UR - http://dx.doi.org/10.1016/j.msard.2015.02.003 ER - TY - JOUR LB - 68. AU - Hobart, J AU - Freeman, J AU - Thompson, A TI - Kurtzke scales revisited: the application of psychometric methods to clinical intuition J2 - Brain PY - 2000 VL - 123 SP - 1027 EP - 1040 UR - https://doi.org/10.1093/brain/123.5.1027 ER - TY - JOUR LB - 69. AU - Marcus, JF AU - Waubant, EL TI - Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis J2 - Neurohospitalist PY - 2013 VL - 3 SP - 65 EP - 80 UR - http://dx.doi.org/10.1177/1941874412457183 ER - TY - JOUR LB - 70. AU - Tremlett, H AU - Zhao, Y AU - Rieckmann, P AU - Hutchinson, M TI - New perspectives in the natural history of multiple sclerosis J2 - Neurology PY - 2010 VL - 74 SP - 2004 EP - 2015 UR - http://dx.doi.org/10.1212/WNL.0b013e3181e3973f ER - TY - JOUR LB - 71. AU - Confavreux, C AU - Vukusic, S AU - Moreau, T AU - Adeleine, P TI - Relapses and progression of disability in multiple sclerosis J2 - N Engl J Med PY - 2000 VL - 343 SP - 1430 EP - 1438 UR - http://dx.doi.org/10.1056/NEJM200011163432001 ER - TY - JOUR LB - 72. AU - Kremenchutzky, M AU - Rice, GPA AU - Baskerville, J AU - Wingerchuk, DM AU - Ebers, GC TI - The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease J2 - Brain PY - 2006 VL - 129 SP - 584 EP - 594 UR - https://doi.org/10.1093/brain/awh721 ER - TY - JOUR LB - 73. AU - Confavreux, C AU - Vukusic, S TI - Age at disability milestones in multiple sclerosis J2 - Brain PY - 2006 VL - 129 SP - 595 EP - 605 UR - https://doi.org/10.1093/brain/awh714 ER - TY - JOUR LB - 74. AU - Confavreux, C AU - Vukusic, S TI - The clinical course of multiple sclerosis J2 - Handb Clin Neurol PY - 2014 VL - 122 SP - 343 EP - 369 UR - http://dx.doi.org/10.1016/B978-0-444-52001-2.00014-5 ER - TY - JOUR LB - 75. AU - Kalincik, T TI - Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review J2 - Neuroepidemiology PY - 2015 VL - 44 SP - 199 EP - 214 UR - http://dx.doi.org/10.1159/000382130 ER - TY - JOUR LB - 76. AU - Hirst, C AU - Ingram, G AU - Pearson, O AU - Pickersgill, T AU - Scolding, N AU - Robertson, N TI - Contribution of relapses to disability in multiple sclerosis J2 - J Neurol PY - 2008 VL - 255 SP - 280 EP - 287 UR - http://dx.doi.org/10.1007/s00415-008-0743-8 ER - TY - JOUR LB - 77. AU - Confavreux, C TI - Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process J2 - Brain PY - 2003 VL - 126 SP - 770 EP - 782 UR - https://doi.org/10.1093/brain/awg081 ER - TY - JOUR LB - 78. AU - Liu, C AU - Blumhardt, LD TI - Disability outcome measures in therapeutic trials of relapsing–remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts J2 - J Neurol Neurosurg Psychiatr PY - 2000 VL - 68 SP - 450 EP - 457 UR - https://doi.org/10.1136/jnnp.68.4.450 ER - TY - JOUR LB - 79. AU - Leray, E AU - Yaouanq, J AU - Le Page, E AU - Coustans, M AU - Laplaud, D AU - Oger, J TI - Evidence for a two-stage disability progression in multiple sclerosis J2 - Brain PY - 2010 VL - 133 SP - 1900 EP - 1913 UR - https://doi.org/10.1093/brain/awq076 ER - TY - JOUR LB - 80. AU - Scalfari, A AU - Neuhaus, A AU - Degenhardt, A AU - Rice, GP AU - Muraro, PA AU - Daumer, M TI - The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability J2 - Brain PY - 2010 VL - 133 SP - 1914 EP - 1929 UR - https://doi.org/10.1093/brain/awq118 ER - TY - JOUR LB - 81. AU - Tremlett, H AU - Yousefi, M AU - Devonshire, V AU - Rieckmann, P AU - Zhao, Y AU - UBC Neurologists TI - Impact of multiple sclerosis relapses on progression diminishes with time J2 - Neurology PY - 2009 VL - 73 SP - 1616 EP - 1623 UR - http://dx.doi.org/10.1212/WNL.0b013e3181c1e44f ER - TY - JOUR LB - 82. AU - Scalfari, A AU - Knappertz, V AU - Cutter, G AU - Goodin, DS AU - Ashton, R AU - Ebers, GC TI - Mortality in patients with multiple sclerosis J2 - Neurology PY - 2013 VL - 81 SP - 184 EP - 192 UR - http://dx.doi.org/10.1212/WNL.0b013e31829a3388 ER - TY - JOUR LB - 83. AU - Manouchehrinia, A AU - Tanasescu, R AU - Tench, CR AU - Constantinescu, CS TI - Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios J2 - J Neurol Neurosurg Psychiatr PY - 2016 VL - 87 SP - 324 EP - 331 UR - http://dx.doi.org/10.1136/jnnp-2015-310361 ER - TY - JOUR LB - 84. AU - Sadovnick, AD AU - Ebers, GC AU - Wilson, RW AU - Paty, DW TI - Life expectancy in patients attending multiple sclerosis clinics J2 - Neurology PY - 1992 VL - 42 SP - 991 EP - 994 UR - https://doi.org/10.1212/WNL.42.5.991 ER - TY - JOUR LB - 85. AU - Kingwell, E AU - Marriott, JJ AU - Jetté, N AU - Pringsheim, T AU - Makhani, N AU - Morrow, SA TI - Incidence and prevalence of multiple sclerosis in Europe: a systematic review J2 - BMC Neurol PY - 2013 VL - 13 SP - 128 UR - http://dx.doi.org/10.1186/1471-2377-13-128 ER - TY - JOUR LB - 86. AU - Jobin, C AU - Larochelle, C AU - Parpal, H AU - Coyle, PK AU - Duquette, P TI - Gender issues in multiple sclerosis: an update J2 - Womens Health PY - 2010 VL - 6 SP - 797 EP - 820 UR - http://dx.doi.org/10.2217/whe.10.69 ER - TY - JOUR LB - 87. AU - Greer, JM AU - McCombe, PA TI - Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms J2 - J Neuroimmunol PY - 2011 VL - 234 SP - 7 EP - 18 UR - http://dx.doi.org/10.1016/j.jneuroim.2011.03.003 ER - TY - JOUR LB - 88. AU - Eikelenboom, MJ AU - Killestein, J AU - Kragt, JJ AU - Uitdehaag, BM AU - Polman, CH TI - Gender differences in multiple sclerosis: cytokines and vitamin D J2 - J Neurol Sci PY - 2009 VL - 286 SP - 40 EP - 42 UR - http://dx.doi.org/10.1016/j.jns.2009.06.025 ER - TY - JOUR LB - 89. AU - Sadovnick, AD TI - European Charcot Foundation Lecture: the natural history of multiple sclerosis and gender J2 - J Neurol Sci PY - 2009 VL - 286 SP - 1 EP - 5 UR - http://dx.doi.org/10.1016/j.jns.2009.09.005 ER - TY - JOUR LB - 90. AU - Ford, HL AU - Gerry, E AU - Airey, CM AU - Vail, A AU - Johnson, MH AU - Williams, DR TI - The prevalence of multiple sclerosis in the Leeds Health Authority J2 - J Neurol Neurosurg Psychiatr PY - 1998 VL - 64 SP - 605 EP - 610 UR - https://doi.org/10.1136/jnnp.64.5.605 ER - TY - JOUR LB - 91. AU - Gray, OM AU - McDonnell, GV AU - Hawkins, SA TI - Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland J2 - Mult Scler PY - 2008 VL - 14 SP - 880 EP - 886 UR - http://dx.doi.org/10.1177/1352458508090663 ER - TY - JOUR LB - 92. AU - Herrett, E AU - Thomas, SL AU - Schoonen, WM AU - Smeeth, L AU - Hall, AJ TI - Validation and validity of diagnoses in the General Practice Research Database: a systematic review J2 - Br J Clin Pharmacol PY - 2010 VL - 69 SP - 4 EP - 14 UR - http://dx.doi.org/10.1111/j.1365-2125.2009.03537.x ER - TY - JOUR LB - 93. AU - Richards, R AU - Sampson, F AU - Beard, S AU - Tappenden, P TI - A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models J2 - Health Technol Assess PY - 2002 VL - 6 IS - 10 UR - https://doi.org/10.3310/hta6100 ER - TY - JOUR LB - 94. AU - Swingler, RJ AU - Compston, DA TI - The morbidity of multiple sclerosis J2 - QJ Med PY - 1992 VL - 83 SP - 325 EP - 337 ER - TY - BOOK LB - 95. AU - MS Society TI - Symptom Management Survey CY - London PB - MS Society PY - 1998 ER - TY - JOUR LB - 96. AU - Einarsson, U AU - Gottberg, K AU - Fredrikson, S AU - von Koch, L AU - Holmqvist, LW TI - Activities of daily living and social activities in people with multiple sclerosis in Stockholm County J2 - Clin Rehabil PY - 2006 VL - 20 SP - 543 EP - 551 UR - https://doi.org/10.1191/0269215506cr953oa ER - TY - JOUR LB - 97. AU - Rodriguez, M AU - Siva, A AU - Ward, J AU - Stolp-Smith, K AU - O’Brien, P AU - Kurland, L TI - Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota J2 - Neurology PY - 1994 VL - 44 SP - 28 EP - 33 UR - https://doi.org/10.1212/WNL.44.1.28 ER - TY - JOUR LB - 98. AU - Wynia, K AU - van Wijlen, AT AU - Middel, B AU - Reijneveld, SA AU - Meilof, JF TI - Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP) J2 - Mult Scler PY - 2012 VL - 18 SP - 654 EP - 661 UR - https://doi.org/10.1177/1352458511423935 ER - TY - JOUR LB - 99. AU - Jones, KH AU - Ford, DV AU - Jones, PA AU - John, A AU - Middleton, RM AU - Lockhart-Jones, H TI - How people with multiple sclerosis rate their quality of life: an EQ-5D survey via the UK MS register J2 - PLOS ONE PY - 2013 VL - 8 SP - e65640 UR - http://dx.doi.org/10.1371/journal.pone.0065640 ER - TY - BOOK LB - 100. AU - Szende, A AU - Bas, J AU - Cabases, J TI - Self-Reported Population Health: An International Perspective Based on EQ-5D ET - 1st edn. CY - Dordrecht PB - Springer Netherlands PY - 2014 ER - TY - JOUR LB - 101. AU - Orme, M AU - Kerrigan, J AU - Tyas, D AU - Russell, N AU - Nixon, R TI - The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK J2 - Value Health PY - 2007 VL - 10 SP - 54 EP - 60 UR - https://doi.org/10.1111/j.1524-4733.2006.00144.x ER - TY - JOUR LB - 102. AU - Siegert, RJ AU - Abernethy, DA TI - Depression in multiple sclerosis: a review J2 - J Neurol Neurosurg Psychiatry PY - 2005 VL - 76 SP - 469 EP - 475 UR - https://doi.org/10.1136/jnnp.2004.054635 ER - TY - JOUR LB - 103. AU - Pompili, M AU - Forte, A AU - Palermo, M AU - Stefani, H AU - Lamis, DA AU - Serafini, G TI - Suicide risk in multiple sclerosis: a systematic review of current literature J2 - J Psychosom Res PY - 2012 VL - 73 SP - 411 EP - 417 UR - http://dx.doi.org/10.1016/j.jpsychores.2012.09.011 ER - TY - JOUR LB - 104. AU - Byford, S AU - Torgerson, DJ AU - Raftery, J TI - Economic note: cost of illness studies J2 - BMJ PY - 2000 VL - 320 SP - 1335 UR - https://doi.org/10.1136/bmj.320.7245.1335 ER - TY - JOUR LB - 105. AU - Kobelt, G AU - Berg, J AU - Lindgren, P AU - Kerrigan, J AU - Russell, N AU - Nixon, R TI - Costs and quality of life of multiple sclerosis in the United Kingdom J2 - Eur J Health Econ PY - 2006 VL - 7 IS - Suppl. 2 SP - 96 EP - 104 UR - http://dx.doi.org/10.1007/s10198-006-0380-z ER - TY - JOUR LB - 106. AU - McCrone, P AU - Heslin, M AU - Knapp, M AU - Bull, P AU - Thompson, A TI - Multiple sclerosis in the UK: service use, costs, quality of life and disability J2 - Pharmacoeconomics PY - 2008 VL - 26 SP - 847 EP - 860 UR - https://doi.org/10.2165/00019053-200826100-00005 ER - TY - JOUR LB - 107. AU - Hawton, AJ AU - Green, C TI - Multiple sclerosis: relapses, resource use, and costs J2 - Eur J Health Econ PY - 2016 VL - 17 SP - 875 EP - 884 UR - http://dx.doi.org/10.1007/s10198-015-0728-3 ER - TY - BOOK LB - 108. AU - Kobelt, G AU - Lindgren, P AU - Parkin, D AU - Francis, DA AU - Johnson, M AU - Bates, D TI - Costs and Quality of Life in Multiple Sclerosis. A Cross-Sectional Observational Study in the UK CY - Stockholm PB - Stockholm School of Economics PY - 2000 ER - TY - JOUR LB - 109. AU - Hakim, EA AU - Bakheit, AM AU - Bryant, TN AU - Roberts, MW AU - McIntosh-Michaelis, SA AU - Spackman, AJ TI - The social impact of multiple sclerosis – a study of 305 patients and their relatives J2 - Disabil Rehabil PY - 2000 VL - 22 SP - 288 EP - 293 UR - https://doi.org/10.1080/096382800296755 ER - TY - JOUR LB - 110. AU - Edwards, RG AU - Barlow, JH AU - Turner, AP TI - Experiences of diagnosis and treatment among people with multiple sclerosis J2 - J Eval Clin Pract PY - 2008 VL - 14 SP - 460 EP - 464 UR - http://dx.doi.org/10.1111/j.1365-2753.2007.00902.x ER - TY - JOUR LB - 111. AU - Johnson, J TI - On receiving the diagnosis of multiple sclerosis: managing the transition J2 - Mult Scler PY - 2003 VL - 9 SP - 82 EP - 88 UR - https://doi.org/10.1191/1352458503ms856oa ER - TY - JOUR LB - 112. AU - Malcomson, KS AU - Lowe-Strong, AS AU - Dunwoody, L TI - What can we learn from the personal insights of individuals living and coping with multiple sclerosis? J2 - Disabil Rehabil PY - 2008 VL - 30 SP - 662 EP - 674 UR - https://doi.org/10.1080/09638280701400730 ER - TY - JOUR LB - 113. AU - Davies, F AU - Edwards, A AU - Brain, K AU - Edwards, M AU - Jones, R AU - Wallbank, R TI - ‘You are just left to get on with it’: qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis J2 - BMJ Open PY - 2015 VL - 5 SP - e007674 UR - https://doi.org/10.1136/bmjopen-2015-007674 ER - TY - JOUR LB - 114. AU - Methley, AM AU - Chew-Graham, C AU - Campbell, S AU - Cheraghi-Sohi, S TI - Experiences of UK health-care services for people with multiple sclerosis: a systematic narrative review J2 - Health Expect PY - 2015 VL - 18 SP - 1844 EP - 1855 UR - http://dx.doi.org/10.1111/hex.12228 ER - TY - JOUR LB - 115. AU - Embrey, N TI - Multiple sclerosis: managing a complex neurological disease J2 - Nurs Stand PY - 2014 VL - 29 SP - 49 EP - 58 UR - http://dx.doi.org/10.7748/ns.29.11.49.e9190 ER - TY - BOOK LB - 116. AU - Zajicek, J AU - Freeman, J AU - Porter, B TI - Multiple Sclerosis Care: A Practical Manual CY - Oxford PB - Oxford University Press PY - 2007 UR - https://doi.org/10.1093/med/9780198569831.001.0001 ER - TY - BOOK LB - 117. AU - National Clinical Guideline Centre TI - Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care CY - London PB - NICE PY - 2014 UR - www.nice.org.uk/guidance/cg186/evidence/full-guideline-193254301 Y2 - 4 November 2015 ER - TY - ELEC LB - 118. AU - National Institute for Health and Care Excellence TI - Alemtuzumab for Treating Relapsing –Remitting Multiple Sclerosis PY - 2014 UR - www.nice.org.uk/guidance/ta312 M1 - 1 June 2016 ER - TY - BOOK LB - 119. AU - National Institute for Health and Care Excellence TI - Dimethyl Fumarate for Treating Relapsing–Remitting Multiple Sclerosis CY - London PB - NICE PY - 2014 ER - TY - BOOK LB - 120. AU - National Institute for Health and Care Excellence TI - Fingolimod for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis CY - London PB - NICE PY - 2012 ER - TY - BOOK LB - 121. AU - National Institute for Health and Care Excellence TI - Natalizumab for the Treatment of Adults with Highly Active Relapsing–Remitting Multiple Sclerosis CY - London PB - NICE PY - 2007 ER - TY - BOOK LB - 122. AU - National Institute for Health and Care Excellence TI - Teriflunomide for Treating Relapsing–Remitting Multiple Sclerosis CY - London PB - NICE PY - 2014 ER - TY - JOUR LB - 123. AU - Hommes, OR AU - Weiner, HL TI - Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis J2 - Mult Scler PY - 2002 VL - 8 SP - 139 EP - 141 UR - https://doi.org/10.1191/1352458502ms791oa ER - TY - JOUR LB - 124. AU - Casetta, I AU - Iuliano, G AU - Filippini, G TI - Azathioprine for multiple sclerosis J2 - Cochrane Database Syst Rev PY - 2007 VL - 4 SP - CD003982 UR - http://dx.doi.org/10.1002/14651858.CD003982.pub2 ER - TY - JOUR LB - 125. AU - Frohman, EM AU - Shah, A AU - Eggenberger, E AU - Metz, L AU - Zivadinov, R AU - Stüve, O TI - Corticosteroids for multiple sclerosis: I. Application for treating exacerbations J2 - Neurotherapeutics PY - 2007 VL - 4 SP - 618 EP - 626 UR - https://doi.org/10.1016/j.nurt.2007.07.008 ER - TY - JOUR LB - 126. AU - Perry, M AU - Swain, S AU - Kemmis-Betty, S AU - Cooper, P AU - Guideline Development Group of the National Institute for Health and Care Excellence TI - Multiple sclerosis: summary of NICE guidance J2 - BMJ PY - 2014 VL - 349 SP - g5701 UR - https://doi.org/10.1136/bmj.g5701 ER - TY - JOUR LB - 127. AU - Shakespeare, DT AU - Boggild, M AU - Young, C TI - Anti-spasticity agents for multiple sclerosis J2 - Cochrane Database Syst Rev PY - 2003 VL - 4 SP - CD001332 UR - https://doi.org/10.1002/14651858.cd001332 ER - TY - JOUR LB - 128. AU - He, D AU - Zhang, Y AU - Dong, S AU - Wang, D AU - Gao, X AU - Zhou, H TI - Pharmacological treatment for memory disorder in multiple sclerosis J2 - Cochrane Database Syst Rev PY - 2013 VL - 12 SP - CD008876 UR - http://dx.doi.org/10.1002/14651858.CD008876.pub3 ER - TY - JOUR LB - 129. AU - Fiest, KM AU - Walker, JR AU - Bernstein, CN AU - Graff, LA AU - Zarychanski, R AU - Abou-Setta, AM TI - Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis J2 - Mult Scler Relat Disord PY - 2016 VL - 5 SP - 12 EP - 26 UR - http://dx.doi.org/10.1016/j.msard.2015.10.004 ER - TY - GEN LB - 130. AU - National Institute for Health and Care Excellence TI - Multiple Sclerosis in Adults: Management PY - 2014 UR - www.nice.org.uk/guidance/cg186 Y2 - 1 June 2016 ER - TY - JOUR LB - 131. AU - Gallien, P AU - Nicolas, B AU - Robineau, S AU - Pétrilli, S AU - Houedakor, J AU - Durufle, A TI - Physical training and multiple sclerosis J2 - Ann Readapt Med Phys PY - 2007 VL - 50 SP - 373 EP - 376 ER - TY - JOUR LB - 132. AU - Gutierrez, GM AU - Chow, JW AU - Tillman, MD AU - McCoy, SC AU - Castellano, V AU - White, LJ TI - Resistance training improves gait kinematics in persons with multiple sclerosis J2 - Arch Phys Med Rehabil PY - 2005 VL - 86 SP - 1824 EP - 1829 UR - https://doi.org/10.1016/j.apmr.2005.04.008 ER - TY - JOUR LB - 133. AU - Petajan, JH AU - White, AT TI - Recommendations for physical activity in patients with multiple sclerosis J2 - Sports Med PY - 1999 VL - 27 SP - 179 EP - 191 UR - https://doi.org/10.2165/00007256-199927030-00004 ER - TY - JOUR LB - 134. AU - Wiles, CM AU - Newcombe, RG AU - Fuller, KJ AU - Shaw, S AU - Furnival-Doran, J AU - Pickersgill, TP AU - Morgan, A TI - Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis J2 - J Neurol Neurosurg Psychiatr PY - 2001 VL - 70 SP - 174 EP - 179 UR - https://doi.org/10.1136/jnnp.70.2.174 ER - TY - JOUR LB - 135. AU - Asano, M AU - Dawes, DJ AU - Arafah, A AU - Moriello, C AU - Mayo, NE TI - What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials? J2 - Mult Scler PY - 2009 VL - 15 SP - 412 EP - 421 UR - https://doi.org/10.1177/1352458508101877 ER - TY - JOUR LB - 136. AU - Asano, M AU - Finlayson, ML TI - Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication J2 - Mult Scler Int PY - 2014 VL - 2014 SP - 798285 UR - https://doi.org/10.1155/2014/798285 ER - TY - ELEC LB - 137. AU - Rashid, WC AU - Jackson, A AU - McFadden, K AU - Meriman, E AU - Vernon, K TI - Symptomatic Management of Multiple Sclerosis in Primary Care PY - 2013 UR - https://community.mssociety.org.uk/sites/default/files/resources/resource_files/Symptomatic%20management%20of%20MS%20in%20primary%20care%20-%20MGP%20guideline.pdf M1 - 28 October 2015 ER - TY - ELEC LB - 138. AU - National institute for Health and Care Excellence TI - Urinary Incontinence in Neurological Disease: Assessment and Management PY - 2012 UR - www.nice.org.uk/guidance/cg148 M1 - 15 October 2015 ER - TY - JOUR LB - 139. AU - Flood, S AU - Foley, FW AU - Zemon, V AU - Picone, M AU - Bongardino, M AU - Quinn, H TI - Predictors of changes in suicidality in multiple sclerosis over time J2 - Disabil Rehabil PY - 2014 VL - 36 SP - 844 EP - 847 UR - http://dx.doi.org/10.3109/09638288.2013.822570 ER - TY - JOUR LB - 140. AU - Mikula, P AU - Nagyova, I AU - Krokavcova, M AU - Vitkova, M AU - Rosenberger, J AU - Szilasiova, J TI - Coping and its importance for quality of life in patients with multiple sclerosis J2 - Disabil Rehabil PY - 2014 VL - 36 SP - 732 EP - 736 UR - http://dx.doi.org/10.3109/09638288.2013.808274 ER - TY - GEN LB - 141. AU - National Institute for Health and Care Excellence TI - Multiple Technology Appraisal. Beta Interferon and Glatiramer Acetate for Treating Multiple Sclerosis (Review of TA32). Final Scope Updated Post Invitation PY - 2016 CY - London PB - NICE ER - TY - JOUR LB - 142. AU - Dhib-Jalbut, S TI - Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis J2 - Neurology PY - 2002 VL - 58 IS - Suppl. 8 SP - 3 EP - 9 UR - https://doi.org/10.1212/WNL.58.8_suppl_4.S3 ER - TY - JOUR LB - 143. AU - Scagnolari, C AU - Selvaggi, C AU - Di Biase, E AU - Fraulo, M AU - Dangond, F AU - Antonelli, G TI - In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis J2 - J Immunoassay Immunochem PY - 2014 VL - 35 SP - 288 EP - 299 UR - https://doi.org/10.1080/15321819.2013.848815 ER - TY - JOUR LB - 144. AU - Antonetti, F AU - Finocchiaro, O AU - Mascia, M AU - Terlizzese, MG AU - Jaber, A TI - A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing–remitting multiple sclerosis J2 - J Interferon Cytokine Res PY - 2002 VL - 22 SP - 1181 EP - 1184 UR - https://doi.org/10.1089/10799900260475696 ER - TY - JOUR LB - 145. AU - Sørensen, PS AU - Deisenhammer, F AU - Duda, P AU - Hohlfeld, R AU - Myhr, KM AU - Palace, J TI - Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis J2 - Eur J Neurol PY - 2005 VL - 12 SP - 817 EP - 827 UR - https://doi.org/10.1111/j.1468-1331.2005.01386.x ER - TY - JOUR LB - 146. AU - Sørensen, PS TI - Neutralizing antibodies against interferon-beta J2 - Ther Adv Neurol Disord PY - 2008 VL - 1 SP - 125 EP - 141 UR - http://dx.doi.org/10.1177/1756285608095144 ER - TY - JOUR LB - 147. AU - Govindappa, K AU - Sathish, J AU - Park, K AU - Kirkham, J AU - Pirmohamed, M TI - Development of interferon beta-neutralising antibodies in multiple sclerosis – a systematic review and meta-analysis J2 - Eur J Clin Pharmacol PY - 2015 VL - 71 SP - 1287 EP - 1298 UR - http://dx.doi.org/10.1007/s00228-015-1921-0 ER - TY - JOUR LB - 148. AU - Bertolotto, A AU - Capobianco, M AU - Amato, MP AU - Capello, E AU - Capra, R AU - Centonze, D TI - Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group J2 - Neurol Sci PY - 2014 VL - 35 SP - 307 EP - 316 UR - https://doi.org/10.1007/s10072-013-1616-1 ER - TY - ELEC LB - 149. AU - Health and Social Care Information Centre TI - Hospital Prescribing: England, 2013–14 PY - 2014 UR - http://digital.nhs.uk/catalogue/PUB15883 M1 - 20 October 2015 ER - TY - JOUR LB - 150. AU - Aharoni, R TI - The mechanism of action of glatiramer acetate in multiple sclerosis and beyond J2 - Autoimmun Rev PY - 2013 VL - 12 SP - 543 EP - 553 UR - http://dx.doi.org/10.1016/j.autrev.2012.09.005 ER - TY - ELEC LB - 151. AU - Department of Health TI - Cost Effective Provision of Disease Modifying Therapies for People with Multiple Sclerosis PY - 2002 UR - http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Healthservicecirculars/DH_4004332 M1 - 4 October 2015 ER - TY - JOUR LB - 152. AU - Kingwell, E AU - van der Kop, M AU - Zhao, Y AU - Shirani, A AU - Zhu, F AU - Oger, J TI - Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada J2 - J Neurol Neurosurg Psychiatry PY - 2012 VL - 83 SP - 61 EP - 66 UR - https://doi.org/10.1136/jnnp-2011-300616 ER - TY - JOUR LB - 153. AU - Palace, J AU - Bregenzer, T AU - Tremlett, H AU - Oger, J AU - Zhu, F AU - Zhu, F TI - UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model J2 - BMJ Open PY - 2014 VL - 4 SP - e004073 UR - http://dx.doi.org/10.1136/bmjopen-2013-004073 ER - TY - JOUR LB - 154. AU - Palace, J AU - Duddy, M AU - Bregenzer, T AU - Lawton, M AU - Zhu, F AU - Boggild, M TI - Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator J2 - Lancet Neurol PY - 2015 VL - 14 SP - 497 EP - 505 UR - https://doi.org/10.1016/S1474-4422(15)00018-6 ER - TY - CONF LB - 155. AU - Palace, J AU - Bregenzer, T AU - Tremlett, H AU - Duddy, M AU - Boggild, M AU - Zhu, F TI - Modelling natural history for the UK multiple sclerosis risk-sharing scheme T2 - 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 18th Annual Conference of Rehabilitation in MS (RIMS) DA - October 2014 CY - Copenhagen, Denmark ER - TY - BOOK LB - 156. AU - National Institute for Health and Care Excellence TI - Guide to the Methods of Technology Appraisal 2013 CY - London PB - NICE PY - 2013 UR - http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9 Y2 - 1 June 2016 ER - TY - JOUR LB - 157. AU - La Mantia, L AU - Di Pietrantonj, C AU - Rovaris, M AU - Rigon, G AU - Frau, S AU - Berardo, F TI - Interferons-beta versus glatiramer acetate for relapsing–remitting multiple sclerosis J2 - Cochrane Database Syst Rev PY - 2014 VL - 7 SP - CD009333 UR - https://doi.org/10.1002/14651858.cd009333.pub2 ER - TY - JOUR LB - 158. AU - Clerico, M AU - Faggiano, F AU - Palace, J AU - Rice, G AU - Tintore, M AU - Durelli, L TI - Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis J2 - Cochrane Database Syst Rev PY - 2008 VL - 2 SP - CD005278 UR - https://doi.org/10.1002/14651858.cd005278.pub3 ER - TY - JOUR LB - 159. AU - Tramacere, I AU - Del Giovane, C AU - Salanti, G AU - D’Amico, R AU - Filippini, G TI - Immunomodulators and immunosuppressants for relapsing–remitting multiple sclerosis: a network meta-analysis J2 - Cochrane Database Syst Rev PY - 2015 VL - 9 SP - CD011381 UR - http://dx.doi.org/10.1002/14651858.CD011381.pub2 ER - TY - JOUR LB - 160. AU - Filippini, G AU - Del Giovane, C AU - Vacchi, L AU - D’Amico, R AU - Di Pietrantonj, C AU - Beecher, D AU - Salanti, G TI - Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis J2 - Cochrane Database Syst Rev PY - 2013 VL - 6 SP - CD008933 UR - http://dx.doi.org/10.1002/14651858.CD008933.pub2 ER - TY - JOUR LB - 161. AU - La Mantia, L AU - Vacchi, L AU - Di Pietrantonj, C AU - Ebers, G AU - Rovaris, M AU - Fredrikson, S AU - Filippini, G TI - Interferon beta for secondary progressive multiple sclerosis J2 - Cochrane Database Syst Rev PY - 2012 VL - 1 SP - CD005181 UR - http://dx.doi.org/10.1002/14651858.CD005181.pub3 ER - TY - ELEC LB - 162. AU - Northern and Yorkshire Regional Drug & Therapeutics Centre TI - Assessment of Interferon-Beta and Glatiramer for the Treatment of Multiple Sclerosis CY - London PB - NICE PY - 2000 UR - www.nice.org.uk/guidance/TA32/documents/original-hta-report-april-20002 M1 - 10 October 2015 ER - TY - JOUR LB - 163. AU - Moher, D AU - Liberati, A AU - Tetzlaff, J AU - Altman, DG AU - the PRISMA Group TI - Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement J2 - BMJ PY - 2009 VL - 339 SP - b2535 UR - https://doi.org/10.1136/bmj.b2535 ER - TY - JOUR LB - 164. AU - Shea, BJ AU - Hamel, C AU - Wells, GA AU - Bouter, LM AU - Kristjansson, E AU - Grimshaw, J TI - AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews J2 - J Clin Epidemiol PY - 2009 VL - 62 SP - 1013 EP - 1020 UR - http://dx.doi.org/10.1016/j.jclinepi.2008.10.009 ER - TY - JOUR LB - 165. AU - Higgins, JP AU - Altman, DG AU - Gøtzsche, PC AU - Jüni, P AU - Moher, D AU - Oxman, AD TI - The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials J2 - BMJ PY - 2011 VL - 343 SP - d5928 UR - http://dx.doi.org/10.1136/bmj.d5928 ER - TY - BOOK LB - 166. AU - Centre for Reviews and Dissemination TI - Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care CY - York PB - Centre for Reviews and Dissemination, University of York PY - 2009 UR - www.york.ac.uk/media/crd/Systematic_Reviews.pdf Y2 - 1 December 2015 ER - TY - JOUR LB - 167. AU - Tierney, JF AU - Stewart, LA AU - Ghersi, D AU - Burdett, S AU - Sydes, MR TI - Practical methods for incorporating summary time-to-event data into meta-analysis J2 - Trials PY - 2007 VL - 8 SP - 16 UR - https://doi.org/10.1186/1745-6215-8-16 ER - TY - JOUR LB - 168. AU - Higgins, JP AU - Jackson, D AU - Barrett, JK AU - Lu, G AU - Ades, AE AU - White, IR TI - Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies J2 - Res Synth Methods PY - 2012 VL - 3 SP - 98 EP - 110 UR - http://dx.doi.org/10.1002/jrsm.1044 ER - TY - JOUR LB - 169. AU - Frohman, EM AU - Goodin, DS AU - Calabresi, PA AU - Corboy, JR AU - Coyle, PK AU - Filippi, M TI - The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology J2 - Neurology PY - 2003 VL - 61 SP - 602 EP - 611 UR - https://doi.org/10.1212/01.WNL.0000082654.99838.EF ER - TY - JOUR LB - 170. AU - Bornstein, MB AU - Miller, A AU - Slagle, S AU - Weitzman, M AU - Crystal, H AU - Drexler, E TI - A pilot trial of Cop 1 in exacerbating–remitting multiple sclerosis J2 - N Engl J Med PY - 1987 VL - 317 SP - 408 EP - 414 UR - https://doi.org/10.1056/NEJM198708133170703 ER - TY - JOUR LB - 171. AU - Kappos, L AU - Polman, CH AU - Freedman, MS AU - Edan, G AU - Hartung, HP AU - Miller, DH TI - Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes J2 - Neurology PY - 2006 VL - 67 SP - 1242 EP - 1249 UR - https://doi.org/10.1212/01.wnl.0000237641.33768.8d ER - TY - JOUR LB - 172. AU - Jacobs, LD AU - Beck, RW AU - Simon, JH AU - Kinkel, RP AU - Brownscheidle, CM AU - Murray, TJ TI - Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group J2 - N Engl J Med PY - 2000 VL - 343 SP - 898 EP - 904 UR - https://doi.org/10.1056/NEJM200009283431301 ER - TY - JOUR LB - 173. AU - Pakdaman, H AU - Sahraian, MA AU - Fallah, A AU - Pakdaman, R AU - Ghareghozli, K AU - Ghafarpour, M TI - Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event J2 - Acta Neurol Scand PY - 2007 VL - 115 SP - 429 EP - 431 UR - https://doi.org/10.1111/j.1600-0404.2007.00813.x ER - TY - JOUR LB - 174. AU - Comi, G AU - Martinelli, V AU - Rodegher, M AU - Moiola, L AU - Bajenaru, O AU - Carra, A TI - Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial J2 - Lancet PY - 2009 VL - 374 SP - 1503 EP - 1511 UR - https://doi.org/10.1016/S0140-6736(09)61259-9 ER - TY - JOUR LB - 175. AU - Comi, G AU - De Stefano, N AU - Freedman, MS AU - Barkhof, F AU - Polman, CH AU - Uitdehaag, BMJ TI - Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial J2 - Lancet Neurol PY - 2012 VL - 11 SP - 33 EP - 41 UR - https://doi.org/10.1016/S1474-4422(11)70262-9 ER - TY - JOUR LB - 176. AU - Beck, RW AU - Chandler, DL AU - Cole, SR AU - Simon, JH AU - Jacobs, LD AU - Kinkel, RP TI - Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses J2 - Ann Neurol PY - 2002 VL - 51 SP - 481 EP - 490 UR - https://doi.org/10.1002/ana.10148 ER - TY - JOUR LB - 177. AU - O’Connor, P AU - Kinkel, RP AU - Kremenchutzky, M TI - Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria J2 - Mult Scler PY - 2009 VL - 15 SP - 728 EP - 734 UR - http://dx.doi.org/10.1177/1352458509103173 ER - TY - JOUR LB - 178. AU - Freedman, MS AU - De Stefano, N AU - Barkhof, F AU - Polman, CH AU - Comi, G AU - Uitdehaag, BM TI - Patient subgroup analyses of the treatment effect of subcutaneous interferon beta-1a on development of multiple sclerosis in the randomized controlled REFLEX study J2 - J Neurol PY - 2014 VL - 261 SP - 490 EP - 499 UR - https://doi.org/10.1007/s00415-013-7222-6 ER - TY - JOUR LB - 179. AU - Polman, C AU - Kappos, L AU - Freedman, MS AU - Edan, G AU - Hartung, HP AU - Miller, DH TI - Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b J2 - J Neurol PY - 2008 VL - 255 SP - 480 EP - 487 UR - http://dx.doi.org/10.1007/s00415-007-0733-2 ER - TY - JOUR LB - 180. AU - Penner, IK AU - Stemper, B AU - Calabrese, P AU - Freedman, MS AU - Polman, CH AU - Edan, G TI - Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis J2 - Mult Scler PY - 2012 VL - 18 SP - 1466 EP - 1471 UR - https://doi.org/10.1177/1352458512442438 ER - TY - JOUR LB - 181. AU - Schwartz, CE AU - Coulthard-Morris, L AU - Cole, B AU - Vollmer, T TI - The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis J2 - Arch Neurol PY - 1997 VL - 54 SP - 1475 EP - 1480 UR - https://doi.org/10.1001/archneur.1997.00550240029009 ER - TY - ELEC LB - 182. AU - Bayer HealthCare TI - Clinical Study Synopsis: The AVANTAGE Study – A Randomized, Multicenter, Phase IV, Open-Label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) or after a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®) PY - 2013 UR - http://trialfinder.pharma.bayer.com/omr/online/91489_Study_Synopsis_CTP.pdf M1 - 1 May 2016 ER - TY - JOUR LB - 183. AU - Rieckmann, P AU - Heidenreich, F AU - Sailer, M AU - Zettl, UK AU - Zessack, N AU - Hartung, HP TI - Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis J2 - Ther Adv Neurol Disord PY - 2012 VL - 5 SP - 3 EP - 12 UR - https://doi.org/10.1177/1756285611428503 ER - TY - JOUR LB - 184. AU - Cadavid, D AU - Wolansky, LJ AU - Skurnick, J AU - Lincoln, J AU - Cheriyan, J AU - Szczepanowski, K TI - Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study J2 - Neurology PY - 2009 VL - 72 SP - 1976 EP - 1983 UR - http://dx.doi.org/10.1212/01.wnl.0000345970.73354.17 ER - TY - JOUR LB - 185. AU - Etemadifar, M AU - Janghorbani, M AU - Shaygannejad, V TI - Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing–remitting multiple sclerosis J2 - Acta Neurol Scand PY - 2006 VL - 113 SP - 283 EP - 287 UR - https://doi.org/10.1111/j.1600-0404.2006.00585.x ER - TY - JOUR LB - 186. AU - Mokhber, N AU - Azarpazhooh, A AU - Orouji, E AU - Rao, SM AU - Khorram, B AU - Sahraian, MA TI - Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial J2 - J Neurol Sci PY - 2014 VL - 342 SP - 16 EP - 20 UR - https://doi.org/10.1016/j.jns.2014.01.038 ER - TY - JOUR LB - 187. AU - Mokhber, N AU - Azarpazhooh, A AU - Orouji, E AU - Khorram, B AU - Modares Gharavi, M AU - Kakhi, S TI - Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis J2 - Psychiatry Clin Neurosci PY - 2015 VL - 69 SP - 649 EP - 657 UR - http://dx.doi.org/10.1111/pcn.12308 ER - TY - JOUR LB - 188. AU - Calabrese, M AU - Bernardi, V AU - Atzori, M AU - Mattisi, I AU - Favaretto, A AU - Rinaldi, F TI - Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis J2 - Mult Scler PY - 2012 VL - 18 SP - 418 EP - 424 UR - http://dx.doi.org/10.1177/1352458510394702 ER - TY - JOUR LB - 189. AU - PRISMS Study Group TI - Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group J2 - Lancet PY - 1998 VL - 352 SP - 1498 EP - 1504 UR - https://doi.org/10.1016/S0140-6736(98)03334-0 ER - TY - JOUR LB - 190. AU - O’Connor, P AU - Filippi, M AU - Arnason, B AU - Comi, G AU - Cook, S AU - Goodin, D TI - 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study J2 - Lancet Neurol PY - 2009 VL - 8 SP - 889 EP - 897 UR - https://doi.org/10.1016/S1474-4422(09)70226-1 ER - TY - JOUR LB - 191. AU - Lublin, FD AU - Cofield, SS AU - Cutter, GR AU - Conwit, R AU - Narayana, PA AU - Nelson, F TI - Randomized study combining interferon and glatiramer acetate in multiple sclerosis J2 - Ann Neurol PY - 2013 VL - 73 SP - 327 EP - 340 UR - http://dx.doi.org/10.1002/ana.23863 ER - TY - JOUR LB - 192. AU - Mikol, DD AU - Barkhof, F AU - Chang, P AU - Coyle, PK AU - Jeffery, DR AU - Schwid, SR TI - Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial J2 - Lancet Neurol PY - 2008 VL - 7 SP - 903 EP - 914 UR - https://doi.org/10.1016/S1474-4422(08)70200-X ER - TY - JOUR LB - 193. AU - Panitch, H AU - Goodin, DS AU - Francis, G AU - Chang, P AU - Coyle, PK AU - O’Connor, P TI - Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial J2 - Neurology PY - 2002 VL - 59 SP - 1496 EP - 1506 UR - https://doi.org/10.1212/01.WNL.0000034080.43681.DA ER - TY - JOUR LB - 194. AU - Panitch, H AU - Goodin, DS AU - Francis, G AU - Chang, P AU - Coyle, PK AU - O’Connor, P TI - Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial J2 - J Neurol Sci PY - 2005 VL - 239 SP - 67 EP - 74 UR - https://doi.org/10.1016/j.jns.2005.08.003 ER - TY - JOUR LB - 195. AU - Schwid, SR AU - Panitch, HS TI - Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis J2 - Clin Ther PY - 2007 VL - 29 SP - 2031 EP - 2048 UR - https://doi.org/10.1016/j.clinthera.2007.09.025 ER - TY - JOUR LB - 196. AU - Durelli, L AU - Verdun, E AU - Barbero, P AU - Bergui, M AU - Versino, E AU - Ghezzi, A TI - Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) J2 - Lancet PY - 2002 VL - 359 SP - 1453 EP - 1460 UR - https://doi.org/10.1016/S0140-6736(02)08430-1 ER - TY - JOUR LB - 197. AU - Singer, B AU - Bandari, D AU - Cascione, M AU - LaGanke, C AU - Huddlestone, J AU - Bennett, R TI - Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonbeta-1a versus subcutaneous interferonbeta-1b: results of the randomized, multicenter, Phase IIIb REFORMS study J2 - BMC Neurol PY - 2012 VL - 12 SP - 154 UR - https://doi.org/10.1186/1471-2377-12-154 ER - TY - JOUR LB - 198. AU - Vollmer, TL AU - Sorensen, PS AU - Selmaj, K AU - Zipp, F AU - Havrdova, E AU - Cohen, JA TI - A randomized placebo-controlled Phase III trial of oral laquinimod for multiple sclerosis J2 - J Neurol PY - 2014 VL - 261 SP - 773 EP - 783 UR - http://dx.doi.org/10.1007/s00415-014-7264-4 ER - TY - JOUR LB - 199. AU - Kappos, L AU - Li, D AU - Calabresi, PA AU - O’Connor, P AU - Bar-Or, A AU - Barkhof, F TI - Ocrelizumab in relapsing–remitting multiple sclerosis: a Phase 2, randomised, placebo-controlled, multicentre trial J2 - Lancet PY - 2011 VL - 378 SP - 1779 EP - 1787 UR - https://doi.org/10.1016/S0140-6736(11)61649-8 ER - TY - JOUR LB - 200. AU - Jacobs, LD AU - Cookfair, DL AU - Rudick, RA AU - Herndon, RM AU - Richert, JR AU - Salazar, AM TI - Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) J2 - Ann Neurol PY - 1996 VL - 39 SP - 285 EP - 294 UR - https://doi.org/10.1002/ana.410390304 ER - TY - JOUR LB - 201. AU - Rudick, RA AU - Goodkin, DE AU - Jacobs, LD AU - Cookfair, DL AU - Herndon, RM AU - Richert, JR TI - Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) J2 - Neurology PY - 1997 VL - 49 SP - 358 EP - 363 UR - https://doi.org/10.1212/WNL.49.2.358 ER - TY - JOUR LB - 202. AU - Goodkin, DE AU - Priore, RL AU - Wende, KE AU - Campion, M AU - Bourdette, DN AU - Herndon, RM TI - Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG) J2 - Mult Scler PY - 1998 VL - 4 SP - 480 EP - 486 UR - https://doi.org/10.1177/135245859800400604 ER - TY - JOUR LB - 203. AU - Fischer, JS AU - Priore, RL AU - Jacobs, LD AU - Cookfair, DL AU - Rudick, RA AU - Herndon, RM TI - Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group J2 - Ann Neurol PY - 2000 VL - 48 SP - 885 EP - 892 UR - https://doi.org/10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1 ER - TY - JOUR LB - 204. AU - Granger, CV AU - Wende, K AU - Brownscheidle, CM TI - Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing–remitting multiple sclerosis J2 - Am J Phys Med Rehabil PY - 2003 VL - 82 SP - 427 EP - 436 UR - https://doi.org/10.1097/01.PHM.0000069189.86581.08 ER - TY - JOUR LB - 205. AU - Miller, DM AU - Weinstock-Guttman, B AU - Bourdette, D AU - You, X AU - Foulds, P AU - Rudick, RA TI - Change in quality of life in patients with relapsing–remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a J2 - Mult Scler PY - 2011 VL - 17 SP - 734 EP - 742 UR - https://doi.org/10.1177/1352458510397221 ER - TY - JOUR LB - 206. AU - Sandberg-Wollheim, M AU - Bever, C AU - Carter, J AU - Färkkilä, M AU - Hurwitz, B AU - Lapierre, Y TI - Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study J2 - J Neurol PY - 2005 VL - 252 SP - 8 EP - 13 UR - http://dx.doi.org/10.1007/s00415-005-0589-2 ER - TY - JOUR LB - 207. AU - De Stefano, N AU - Sormani, MP AU - Stubinski, B AU - Blevins, G AU - Drulovic, JS AU - Issard, D TI - Efficacy and safety of subcutaneous interferon β-1a in relapsing–remitting multiple sclerosis: further outcomes from the IMPROVE study J2 - J Neurol Sci PY - 2012 VL - 312 SP - 97 EP - 101 UR - https://doi.org/10.1016/j.jns.2011.08.013 ER - TY - JOUR LB - 208. AU - Patten, SB AU - Metz, LM TI - Interferon beta-1 a and depression in relapsing–remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial J2 - Mult Scler PY - 2001 VL - 7 SP - 243 EP - 248 ER - TY - JOUR LB - 209. AU - IFNB Multiple Sclerosis Study Group TI - Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group J2 - Neurology PY - 1993 VL - 43 SP - 655 EP - 661 UR - https://doi.org/10.1212/WNL.43.4.655 ER - TY - JOUR LB - 210. AU - IFNB Multiple Sclerosis Study Group AU - University of British Columbia MS/MRI Analysis Group TI - Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial J2 - Neurology PY - 1995 VL - 45 SP - 1277 EP - 1285 UR - https://doi.org/10.1212/WNL.45.7.1277 ER - TY - JOUR LB - 211. AU - Knobler, RL AU - Greenstein, JI AU - Johnson, KP AU - Lublin, FD AU - Panitch, HS AU - Conway, K TI - Systemic recombinant human interferon-beta treatment of relapsing–remitting multiple sclerosis: pilot study analysis and six-year follow-up J2 - J Interferon Res PY - 1993 VL - 13 SP - 333 EP - 340 UR - https://doi.org/10.1089/jir.1993.13.333 ER - TY - JOUR LB - 212. AU - Cadavid, D AU - Kim, S AU - Peng, B AU - Skurnick, J AU - Younes, M AU - Hill, J TI - Clinical consequences of MRI activity in treated multiple sclerosis J2 - Mult Scler PY - 2011 VL - 17 SP - 1113 EP - 1121 UR - http://dx.doi.org/10.1177/1352458511405375 ER - TY - JOUR LB - 213. AU - Calabresi, PA AU - Kieseier, BC AU - Arnold, DL AU - Balcer, LJ AU - Boyko, A AU - Pelletier, J TI - Pegylated interferon beta-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study J2 - Lancet Neurol PY - 2014 VL - 13 SP - 657 EP - 665 UR - https://doi.org/10.1016/S1474-4422(14)70068-7 ER - TY - JOUR LB - 214. AU - Arnold, DL AU - Calabresi, PA AU - Kieseier, BC AU - Sheikh, SI AU - Deykin, A AU - Zhu, Y TI - Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing–remitting multiple sclerosis J2 - BMC Neurol PY - 2014 VL - 14 SP - 240 UR - https://doi.org/10.1186/s12883-014-0240-x ER - TY - JOUR LB - 215. AU - Newsome, SD AU - Guo, S AU - Altincatal, A AU - Proskorovsky, I AU - Kinter, E AU - Phillips, G TI - Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis J2 - Mult Scler Relat Disord PY - 2015 VL - 4 SP - 350 EP - 357 UR - http://dx.doi.org/10.1016/j.msard.2015.06.004 ER - TY - JOUR LB - 216. AU - Fox, RJ AU - Miller, DH AU - Phillips, JT AU - Hutchinson, M AU - Havrdova, E AU - Kita, M TI - Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis J2 - N Engl J Med PY - 2012 VL - 367 SP - 1087 EP - 1097 UR - https://doi.org/10.1056/NEJMoa1206328 ER - TY - JOUR LB - 217. AU - Johnson, KP AU - Brooks, BR AU - Cohen, JA AU - Ford, CC AU - Goldstein, J AU - Lisak, RP TI - Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group J2 - Neurology PY - 1995 VL - 45 SP - 1268 EP - 1276 UR - https://doi.org/10.1212/WNL.45.7.1268 ER - TY - JOUR LB - 218. AU - Johnson, KP AU - Brooks, BR AU - Cohen, JA AU - Ford, CC AU - Goldstein, J AU - Lisak, RP TI - Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group J2 - Neurology PY - 1998 VL - 50 SP - 701 EP - 708 UR - https://doi.org/10.1212/WNL.50.3.701 ER - TY - JOUR LB - 219. AU - Comi, G AU - Filippi, M AU - Wolinsky, JS TI - European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis J2 - Ann Neurol PY - 2001 VL - 49 SP - 290 EP - 297 UR - https://doi.org/10.1002/ana.64 ER - TY - JOUR LB - 220. AU - Cohen, J AU - Belova, A AU - Selmaj, K AU - Wolf, C AU - Sormani, MP AU - Oberyé, J TI - Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial J2 - JAMA Neurol PY - 2015 VL - 72 SP - 1433 EP - 1441 UR - http://dx.doi.org/10.1001/jamaneurol.2015.2154 ER - TY - JOUR LB - 221. AU - Khan, O AU - Rieckmann, P AU - Boyko, A AU - Selmaj, K AU - Zivadinov, R AU - GALA Study Group TI - Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis J2 - Ann Neurol PY - 2013 VL - 73 SP - 705 EP - 713 UR - http://dx.doi.org/10.1002/ana.23938 ER - TY - JOUR LB - 222. AU - Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis TI - European Study Group on interferon beta-1b in secondary progressive MS J2 - Lancet PY - 1998 VL - 352 SP - 1491 EP - 1497 UR - https://doi.org/10.1016/S0140-6736(98)10039-9 ER - TY - JOUR LB - 223. AU - Panitch, H AU - Miller, A AU - Paty, D AU - Weinshenker, B AU - North American Study Group on Interferon beta-1b in Secondary Progressive MS TI - Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study J2 - Neurology PY - 2004 VL - 63 SP - 1788 EP - 1795 UR - https://doi.org/10.1212/01.WNL.0000146958.77317.3E ER - TY - JOUR LB - 224. AU - SPECTRIMS Study Group TI - Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results J2 - Neurology PY - 2001 VL - 56 SP - 1496 EP - 1504 UR - https://doi.org/10.1212/WNL.56.11.1496 ER - TY - JOUR LB - 225. AU - Kappos, L AU - Polman, C AU - Pozzilli, C AU - Thompson, A AU - Beckmann, K AU - Dahlke, F AU - European Study Group in Interferon beta-1b in Secondary-Progressive MS TI - Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS J2 - Neurology PY - 2001 VL - 57 SP - 1969 EP - 1975 UR - https://doi.org/10.1212/WNL.57.11.1969 ER - TY - JOUR LB - 226. AU - Filippi, M AU - Rocca, MA AU - Camesasca, F AU - Cook, S AU - O’Connor, P AU - Arnason, BG TI - Interferon β-1b and glatiramer acetate effects on permanent black hole evolution J2 - Neurology PY - 2011 VL - 76 SP - 1222 EP - 1228 UR - http://dx.doi.org/10.1212/WNL.0b013e3182143577 ER - TY - JOUR LB - 227. AU - CHAMPS Study Group TI - Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis J2 - Am J Ophthalmol PY - 2001 VL - 132 SP - 463 EP - 471 UR - https://doi.org/10.1016/S0002-9394(01)01209-0 ER - TY - JOUR LB - 228. AU - O’Connor, P AU - CHAMPS TI - The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS J2 - Clin Ther PY - 2003 VL - 25 SP - 2865 EP - 2874 UR - https://doi.org/10.1016/S0149-2918(03)80339-9 ER - TY - JOUR LB - 229. AU - Lindsey, JW AU - Scott, TF AU - Lynch, SG AU - Cofield, SS AU - Nelson, F AU - Conwit, R TI - The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics J2 - Mult Scler Relat Disord PY - 2012 VL - 1 SP - 81 EP - 86 UR - https://doi.org/10.1016/j.msard.2012.01.006 ER - TY - JOUR LB - 230. AU - Kita, M AU - Fox, RJ AU - Phillips, JT AU - Hutchinson, M AU - Havrdova, E AU - Sarda, SP TI - Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study J2 - Mult Scler PY - 2014 VL - 20 SP - 253 EP - 257 UR - https://doi.org/10.1177/1352458513507818 ER - TY - JOUR LB - 231. AU - Gold, R AU - Rieckmann, P AU - Chang, P AU - Abdalla, J AU - PRISMS Study Group TI - The long-term safety and tolerability of high-dose interferon beta-1a in relapsing–remitting multiple sclerosis: 4-year data from the PRISMS study J2 - Eur J Neurol PY - 2005 VL - 12 SP - 649 EP - 656 UR - https://doi.org/10.1111/j.1468-1331.2005.01083.x ER - TY - ELEC LB - 232. TI - Common Drug Review: CDEC Final Recommendation: Interferon Beta-1a (Rebif – EMD Serono Canada Inc.) Indication: Clinically Isolated Syndrome PY - 2013 UR - www.cadth.ca/media/cdr/complete/cdr_complete_Rebif_Aug-19-13.pdf M1 - 1 June 2016 ER - TY - JOUR LB - 233. AU - Salanti, G AU - Ades, AE AU - Ioannidis, JP TI - Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial J2 - J Clin Epidemiol PY - 2011 VL - 64 SP - 163 EP - 171 UR - http://dx.doi.org/10.1016/j.jclinepi.2010.03.016 ER - TY - ELEC LB - 234. AU - European Medicines Agency TI - Plegridy 125 Micrograms Solution for Injection in Pre-filled Pen. Summary of Product Characteristics UR - www.medicines.org.uk/emc/medicine/29370 M1 - 21 April 2017 ER - TY - JOUR LB - 235. AU - Comi, G AU - Martinelli, V AU - Rodegher, M AU - Moiola, L AU - Leocani, L AU - Bajenaru, O TI - Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome J2 - Mult Scler PY - 2013 VL - 19 SP - 1074 EP - 1083 UR - https://doi.org/10.1177/1352458512469695 ER - TY - JOUR LB - 236. AU - Kinkel, RP AU - Kollman, C AU - O’Connor, P AU - Murray, TJ AU - Simon, J AU - Arnold, D TI - IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event J2 - Neurology PY - 2006 VL - 66 SP - 678 EP - 684 UR - https://doi.org/10.1212/01.wnl.0000200778.65597.ae ER - TY - JOUR LB - 237. AU - Kinkel, RP AU - Dontchev, M AU - Kollman, C AU - Skaramagas, TT AU - O’Connor, PW AU - Simon, JH AU - Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators TI - Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance J2 - Arch Neurol PY - 2012 VL - 69 SP - 183 EP - 190 UR - https://doi.org/10.1001/archneurol.2011.1426 ER - TY - JOUR LB - 238. AU - Kieseier, BC AU - Arnold, DL AU - Balcer, LJ AU - Boyko, AA AU - Pelletier, J AU - Liu, S TI - Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE J2 - Mult Scler PY - 2015 VL - 21 SP - 1025 EP - 1035 UR - https://doi.org/10.1177/1352458514557986 ER - TY - ELEC LB - 239. AU - Centre for Reviews and Dissemination TI - Search Strategies: NHS EED UR - www.crd.york.ac.uk/crdweb/searchstrategies.asp#nhseedmedline M1 - 3 January 2016 ER - TY - JOUR LB - 240. AU - Glanville, J AU - Kaunelis, D AU - Mensinkai, S TI - How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE J2 - Int J Technol Assess Health Care PY - 2009 VL - 25 SP - 522 EP - 529 UR - http://dx.doi.org/10.1017/S0266462309990523 ER - TY - JOUR LB - 241. AU - Royle, P AU - Waugh, N TI - Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system J2 - Health Technol Assess PY - 2003 VL - 7 IS - 34 UR - https://doi.org/10.3310/hta7340 ER - TY - ELEC LB - 242. AU - Paisley, S AU - Booth, A AU - Mensinkai, S TI - Etext on Health Technology Assessment (HTA) Information Resources: Chapter 12: Health-related Quality of Life Studies PY - 2005 UR - www.nlm.nih.gov/archive/20060905/nichsr/ehta/chapter12.html M1 - 5 January 2016 ER - TY - JOUR LB - 243. AU - Husereau, D AU - Drummond, M AU - Petrou, S AU - Carswell, C AU - Moher, D AU - Greenberg, D TI - Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement J2 - Int J Technol Assess Health Care PY - 2013 VL - 29 SP - 117 EP - 122 UR - https://doi.org/10.1017/S0266462313000160 ER - TY - JOUR LB - 244. AU - Philips, Z AU - Ginnelly, L AU - Sculpher, M AU - Claxton, K AU - Golder, S AU - Riemsma, R TI - Review of guidelines for good practice in decision-analytic modelling in health technology assessment J2 - Health Technol Assess PY - 2004 VL - 8 IS - 36 UR - https://doi.org/10.3310/hta8360 ER - TY - JOUR LB - 245. AU - Allen, F AU - Montgomery, S AU - Maruszczak, M AU - Kusel, J AU - Adlard, N TI - Convergence yet continued complexity: a systematic review and critique of health economic models of relapsing–remitting multiple sclerosis in the United Kingdom J2 - Value Health PY - 2015 VL - 18 SP - 925 EP - 938 UR - https://doi.org/10.1016/j.jval.2015.05.006 ER - TY - JOUR LB - 246. AU - Castrop, F AU - Haslinger, B AU - Hemmer, B AU - Buck, D TI - Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta J2 - Neuropsychiatr Dis Treat PY - 2013 VL - 9 SP - 1339 EP - 1349 UR - http://dx.doi.org/10.2147/NDT.S33949 ER - TY - JOUR LB - 247. AU - Guo, S AU - Pelligra, C AU - Saint-Laurent Thibault, C AU - Hernandez, L AU - Kansal, A TI - Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches J2 - Pharmacoeconomics PY - 2014 VL - 32 SP - 559 EP - 572 UR - https://doi.org/10.1007/s40273-014-0150-1 ER - TY - JOUR LB - 248. AU - Hawton, A AU - Shearer, J AU - Goodwin, E AU - Green, C TI - Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis J2 - Appl Health Econ Health Policy PY - 2013 VL - 11 SP - 331 EP - 341 UR - http://dx.doi.org/10.1007/s40258-013-0034-0 ER - TY - JOUR LB - 249. AU - Owens, GM AU - Olvey, EL AU - Skrepnek, GH AU - Pill, MW TI - Perspectives for managed care organizations on the burden of multiple sclerosis and the cost–benefits of disease-modifying therapies J2 - J Manag Care Pharm PY - 2013 VL - 19 IS - Suppl. 1 SP - 41 EP - 53 UR - https://doi.org/10.18553/jmcp.2013.19.s1.S41 ER - TY - JOUR LB - 250. AU - Thompson, JP AU - Abdolahi, A AU - Noyes, K TI - Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider J2 - Pharmacoeconomics PY - 2013 VL - 31 SP - 455 EP - 469 UR - http://dx.doi.org/10.1007/s40273-013-0063-4 ER - TY - JOUR LB - 251. AU - Yamamoto, D AU - Campbell, JD TI - Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature J2 - Autoimmune Dis PY - 2012 VL - 2012 SP - 784364 UR - https://doi.org/10.1155/2012/784364 ER - TY - JOUR LB - 252. AU - Zalesak, M AU - Greenbaum, JS AU - Cohen, JT AU - Kokkotos, F AU - Lustig, A AU - Neumann, PJ TI - The value of specialty pharmaceuticals – a systematic review J2 - Am J Manag Care PY - 2014 VL - 20 SP - 461 EP - 472 ER - TY - JOUR LB - 253. AU - Kuspinar, A AU - Mayo, NE TI - A review of the psychometric properties of generic utility measures in multiple sclerosis J2 - Pharmacoeconomics PY - 2014 VL - 32 SP - 759 EP - 773 UR - https://doi.org/10.1007/s40273-014-0167-5 ER - TY - JOUR LB - 254. AU - Fredrikson, S AU - McLeod, E AU - Henry, N AU - Pitcher, A AU - Lowin, J AU - Cuche, M TI - A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden J2 - J Med Econ PY - 2013 VL - 16 SP - 756 EP - 762 UR - http://dx.doi.org/10.3111/13696998.2013.792824 ER - TY - JOUR LB - 255. AU - Kobelt, G AU - Lindgren, P AU - Miltenburger, C AU - Hillert, J TI - Economic evaluation of interferon-angstrom-1b in the treatment of patients with a clinically isolated syndrome (CIS) J2 - Value Health PY - 2007 VL - 10 SP - A385 EP - A386 UR - https://doi.org/10.1016/S1098-3015(10)65357-0 ER - TY - JOUR LB - 256. AU - Lazzaro, C AU - Bianchi, C AU - Peracino, L AU - Zacchetti, P AU - Uccelli, A TI - Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b J2 - Neurol Sci PY - 2009 VL - 30 SP - 21 EP - 31 UR - https://doi.org/10.1007/s10072-009-0015-0 ER - TY - JOUR LB - 257. AU - Iskedjian, M AU - Walker, JH AU - Gray, T AU - Vicente, C AU - Einarson, TR AU - Gehshan, A TI - Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event J2 - Mult Scler PY - 2005 VL - 11 SP - 542 EP - 551 UR - https://doi.org/10.1191/1352458505ms1211oa ER - TY - JOUR LB - 258. AU - Arbizu, T AU - Pinol, C AU - Casado, V TI - Cost–utility of interferon beta-1b in the treatment of patients with a clinically isolated syndrome suggestive of multiple sclerosis in Spain J2 - Value Health PY - 2009 VL - 12 SP - A370 UR - https://doi.org/10.1016/S1098-3015(10)74820-8 ER - TY - JOUR LB - 259. AU - Caloyeras, JP AU - Wang, C AU - Bauer, L AU - Lee, WC AU - Lanius, V AU - Gondek, K TI - Cost–utility of interferon beta-1b in the treatment of patients with a clinically isolated syndrome suggestive of multiple sclerosis J2 - Value Health PY - 2008 VL - 11 SP - A141 UR - https://doi.org/10.1016/S1098-3015(10)70448-4 ER - TY - JOUR LB - 260. AU - Caloyeras, JP AU - Harrow, B AU - Wang, C AU - Beckmann, K AU - Knappertz, V AU - Pohl, C TI - Cost–utility of interferon beta-1B in the treatment of patients with a clinically isolated syndrome suggestive of multiple sclerosis: model utilizing five year benefit data J2 - Value Health PY - 2009 VL - 12 SP - A14 UR - https://doi.org/10.1016/S1098-3015(10)73129-6 ER - TY - JOUR LB - 261. AU - Caloyeras, JP AU - Zhang, B AU - Wang, C AU - Eriksson, M AU - Fredrikson, S AU - Beckmann, K TI - Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis J2 - Clin Ther PY - 2012 VL - 34 SP - 1132 EP - 1144 UR - https://doi.org/10.1016/j.clinthera.2012.03.004 ER - TY - JOUR LB - 262. AU - Zarco, LA AU - Millán, SP AU - Londoño, D AU - Parada, L AU - Taborda, A AU - Borda, MG TI - The cost-effectiveness of interferon beta treatment in patients with a clinically isolated syndrome in Colombia J2 - Biomedica PY - 2014 VL - 34 SP - 110 EP - 117 UR - http://dx.doi.org/10.1590/S0120-41572014000100014 ER - TY - JOUR LB - 263. AU - Comi, G AU - De Stefano, N AU - Freedman, MS AU - Barkhof, F AU - Uitdehaag, BMJ AU - de Vos, M TI - Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the Phase III dosing frequency-blind multicentre REFLEXION study J2 - J Neurol Neurosurg Psychiatry PY - 2017 VL - 88 SP - 285 EP - 294 UR - https://doi.org/10.1136/jnnp-2016-314843 ER - TY - JOUR LB - 264. AU - Sanchez-de la Rosa, R AU - Sabater, E AU - Casado, MA AU - Arroyo, R TI - Cost-effectiveness analysis of disease modifying drugs (interferons and glatiramer acetate) as first line treatments in remitting–relapsing multiple sclerosis patients J2 - J Med Econ PY - 2012 VL - 15 SP - 424 EP - 433 UR - https://doi.org/10.3111/13696998.2012.654868 ER - TY - JOUR LB - 265. AU - Nikfar, S AU - Kebriaeezadeh, A AU - Dinarvand, R AU - Abdollahi, M AU - Sahraian, MA AU - Henry, D TI - Cost-effectiveness of different interferon beta products for relapsing–remitting and secondary progressive multiple sclerosis: decision analysis based on long-term clinical data and switchable treatments J2 - Daru PY - 2013 VL - 21 SP - 50 UR - https://doi.org/10.1186/2008-2231-21-50 ER - TY - JOUR LB - 266. AU - Agashivala, N AU - Kim, E TI - Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis J2 - Clin Ther PY - 2012 VL - 34 SP - 1583 EP - 1590 UR - http://dx.doi.org/10.1016/j.clinthera.2012.06.012 ER - TY - JOUR LB - 267. AU - Pan, F AU - Goh, JW AU - Cutter, G AU - Su, W AU - Pleimes, D AU - Wang, C TI - Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States J2 - Clin Ther PY - 2012 VL - 34 SP - 1966 EP - 1976 UR - http://dx.doi.org/10.1016/j.clinthera.2012.07.010 ER - TY - JOUR LB - 268. AU - Darbà, J AU - Kaskens, L AU - Sánchez-de la Rosa, R TI - Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing–remitting multiple sclerosis, based on the CombiRx study J2 - J Med Econ PY - 2014 VL - 17 SP - 215 EP - 222 UR - http://dx.doi.org/10.3111/13696998.2014.890936 ER - TY - JOUR LB - 269. AU - Imani, A AU - Golestani, M TI - Cost–utility analysis of disease-modifying drugs in relapsing–remitting multiple sclerosis in Iran J2 - Iran J Neurol PY - 2012 VL - 11 SP - 87 EP - 90 ER - TY - JOUR LB - 270. AU - Dembek, C AU - White, LA AU - Quach, J AU - Szkurhan, A AU - Rashid, N AU - Blasco, MR TI - Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain J2 - Eur J Health Econ PY - 2014 VL - 15 SP - 353 EP - 362 UR - http://dx.doi.org/10.1007/s10198-013-0478-z ER - TY - JOUR LB - 271. AU - Chevalier, J AU - Chamoux, C AU - Hammès, F AU - Chicoye, A TI - Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: a French societal perspective J2 - PLOS ONE PY - 2016 VL - 11 SP - e0150703 UR - http://dx.doi.org/10.1371/journal.pone.0150703 ER - TY - JOUR LB - 272. AU - Lee, S AU - Baxter, DC AU - Limone, B AU - Roberts, MS AU - Coleman, CI TI - Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States J2 - J Med Econ PY - 2012 VL - 15 SP - 1088 EP - 1096 UR - http://dx.doi.org/10.3111/13696998.2012.693553 ER - TY - JOUR LB - 273. AU - Khatri, B AU - Barkhof, F AU - Comi, G AU - Hartung, HP AU - Kappos, L AU - Montalban, X TI - Comparison of fingolimod with interferon beta-1a in relapsing–remitting multiple sclerosis: a randomised extension of the TRANSFORMS study J2 - Lancet Neurol PY - 2011 VL - 10 SP - 520 EP - 529 UR - https://doi.org/10.1016/S1474-4422(11)70099-0 ER - TY - BOOK LB - 274. AU - MAG Mutual HealthCare Solutions, Inc TI - Physician’s Fee and Coding Guide CY - Duluth, GA PB - MAG Mutual HealthCare Solutions, Inc. PY - 2010 ER - TY - BOOK LB - 275. AU - Tappenden, P AU - Chilcot, J AU - O’Hagan, T AU - McCabe, C AU - Cooper, N AU - Abrams, K TI - Cost Effectiveness of Beta Interferons and Glatiramer Acetate in the Management of Multiple Sclerosis: Final Report to the National Institute for Clinical Excellence CY - London PB - NICE PY - 2001 UR - www.nice.org.uk/guidance/ta32/resources/assessment-report-on-the-use-of-beta-interferon-and-glatiramer-acetate-for-multiple-sclerosis-scharr-report2 Y2 - 1 June 2016 ER - TY - JOUR LB - 276. AU - Jackson, CH AU - Sharples, LD AU - Thompson, SG AU - Duffy, SW AU - Couto, E TI - Multistate Markov models for disease progression with classification error J2 - JR Stat Soc Ser D Stat PY - 2003 VL - 52 SP - 193 EP - 209 UR - https://doi.org/10.1111/1467-9884.00351 ER - TY - BOOK LB - 277. AU - Office for National Statistics TI - Mortality and Survival CY - London PB - ONS PY - 2010 ER - TY - BOOK LB - 278. AU - Curtis, L AU - Burns, A TI - Unit Costs of Health and Social Care 2015 CY - Canterbury PB - Personal Social Services Research Unit, University of Kent PY - 2015 UR - www.pssru.ac.uk/project-pages/unit-costs/2015/index.php Y2 - 1 June 2016 ER - TY - JOUR LB - 279. AU - Boggild, M AU - Palace, J AU - Barton, P AU - Ben-Shlomo, Y AU - Bregenzer, T AU - Dobson, C AU - Gray, R TI - Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator J2 - BMJ PY - 2009 VL - 339 SP - b4677 UR - https://doi.org/10.1136/bmj.b4677 ER - TY - JOUR LB - 280. AU - Acaster, S AU - Perard, R AU - Chauhan, D AU - Lloyd, AJ TI - A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis J2 - BMC Health Serv Res PY - 2013 VL - 13 SP - 346 UR - http://dx.doi.org/10.1186/1472-6963-13-346 ER - TY - JOUR LB - 281. AU - Scolding, N AU - Barnes, D AU - Cader, S AU - Chataway, J AU - Chaudhuri, A AU - Coles, A TI - Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis J2 - Pract Neurol PY - 2015 VL - 15 SP - 273 EP - 279 UR - https://doi.org/10.1136/practneurol-2015-001139 ER - TY - BOOK LB - 282. AU - Biogen Idec Ltd, Heron Evidence Development TI - Natalizumab (Tysabri®) for the Treatment of Adults with Highly Active Relapsing Remitting Multiple Sclerosis: Biogen Idec Single Technology Appraisal (STA) Submission to the National Institute for Health and Clinical Excellence CY - London PB - NICE PY - 2007 UR - www.nice.org.uk/guidance/TA127/documents/multiple-sclerosis-natalizumab-manufacturer-submissions-biogen-idec-uk-and-elan-pharma-international-ltd-joint-development-agreement-confidential-information-removed2 Y2 - 1 June 2016 ER - TY - JOUR LB - 283. AU - Karampampa, K AU - Gustavsson, A AU - Miltenburger, C AU - Eckert, B TI - Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries J2 - Mult Scler PY - 2012 VL - 18 IS - Suppl. 2 SP - 7 EP - 15 UR - http://dx.doi.org/10.1177/1352458512441566 ER - TY - JOUR LB - 284. AU - Zajicek, JP AU - Ingram, WM AU - Vickery, J AU - Creanor, S AU - Wright, DE AU - Hobart, JC TI - Patient-orientated longitudinal study of multiple sclerosis in south west England (the South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort J2 - BMC Neurol PY - 2010 VL - 10 SP - 88 UR - https://doi.org/10.1186/1471-2377-10-88 ER - TY - BOOK LB - 285. AU - Department of Health TI - NHS Reference Costs 2014 to 2015 CY - London PB - Department of Health PY - 2015 UR - www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015 Y2 - 1 June 2016 ER - TY - JOUR LB - 286. AU - Patzold, U AU - Pocklington, PR TI - Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980 J2 - Acta Neurol Scand PY - 1982 VL - 65 SP - 248 EP - 266 UR - https://doi.org/10.1111/j.1600-0404.1982.tb03084.x ER - TY - JOUR LB - 287. AU - Maruszczak, MJ AU - Montgomery, SM AU - Griffiths, MJ AU - Bergvall, N AU - Adlard, N TI - Cost–utility of fingolimod compared with dimethyl fumarate in highly active relapsing–remitting multiple sclerosis (RRMS) in England J2 - J Med Econ PY - 2015 VL - 18 SP - 874 EP - 885 UR - http://dx.doi.org/10.3111/13696998.2015.1056794 ER - TY - JOUR LB - 288. AU - Tyas, D AU - Kerrigan, J AU - Russell, N AU - Nixon, R TI - The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? J2 - Value Health PY - 2007 VL - 10 SP - 386 EP - 389 UR - https://doi.org/10.1111/j.1524-4733.2007.00192.x ER - TY - JOUR LB - 289. AU - Dee, A AU - Hutchinson, M AU - De La Harpe, D TI - A budget impact analysis of natalizumab use in Ireland J2 - Ir J Med Sci PY - 2012 VL - 181 SP - 199 EP - 204 UR - http://dx.doi.org/10.1007/s11845-011-0773-6 ER - TY - ELEC LB - 290. AU - Office for National Statistics TI - National Life Tables, United Kingdom: 2012–2014 PY - 2015 UR - www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2015-09-23 M1 - June 2017 ER - TY - JOUR LB - 291. AU - Pokorski, RJ TI - Long-term survival experience of patients with multiple sclerosis J2 - J Insur Med PY - 1997 VL - 29 SP - 101 EP - 106 ER - TY - BOOK LB - 292. AU - Genzyme TI - Single Technology Appraisal (STA): Teriflunomide for the Treatment of Relapsing Remitting Multiple Sclerosis in Adults: Manufacturer/Sponsor Submission of Evidence CY - London PB - NICE PY - 2013 UR - www.nice.org.uk/guidance/TA303/documents/multiple-sclerosis-relapsing-teriflunomide-evaluation-report4 Y2 - 1 June 2016 ER - TY - ELEC LB - 293. AU - electronic Medicines Compendium (eMC) TI - Beta Interferon Summary of Product Characteristics (Avonex®, Betaferon®, Extavia®, Plegridy®, Rebif®) UR - www.medicines.org.uk/ M1 - June 2017 ER - TY - BOOK LB - 294. AU - Canadian Agency for Drugs and Technologies in Health TI - Common Drug Review Pharmacoeconomic Review Report: Teriflunomide (Aubagio) CY - Ottawa PB - CADTH PY - 2014 UR - www.cadth.ca/media/pdf/TR0004_RRMS_ScienceReport_e.pdf Y2 - June 2017 ER - TY - JOUR LB - 295. AU - Kerbrat, A AU - Hamonic, S AU - Leray, E AU - Tron, I AU - Edan, G AU - Yaouanq, J AU - West Neuroscience Network of Excellence (WENNE) TI - Ten-year prognosis in multiple sclerosis: a better outcome in relapsing–remitting patients but not in primary progressive patients J2 - Eur J Neurol PY - 2015 VL - 22 SP - 507 EP - e35 UR - http://dx.doi.org/10.1111/ene.12600 ER - TY - JOUR LB - 296. AU - Tolley, K AU - Hutchinson, M AU - You, X AU - Wang, P AU - Sperling, B AU - Taneja, A TI - A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing–remitting multiple sclerosis J2 - PLOS ONE PY - 2015 VL - 10 SP - e0127960 UR - https://doi.org/10.1371/journal.pone.0127960 ER -